申请人:Rorer Pharmaceutical Corporation
公开号:US04677210A1
公开(公告)日:1987-06-30
##STR1## wherein Ar and Ar.sub.1 are each independently phenyl or naphthyl or a nitrogen, oxygen or sulfur-heterocyclic ring; Z is a chemical bond or an alkylene chain containing up to 5 carbons in the principal chain and up to a total of 7 carbons; X is O or S; R and R.sub.1 are independently hydrogen, hydroxy, lower alkoxy, lower alkanoyloxy, halo, cyano, carboloweralkoxy, carboxyloweralkyl, aryloxy or benzyloxy; R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are independently hydrogen, lower alkyl, lower aralkyl, lower alkenyl, lower alkynyl, aryl or carboxyloweralkyl; and pharmaceutically acceptable salts thereof have pharmaceutical activity, particularly as lipoxygenase inhibitors possessing anti-inflammatory and anti-allergic properties.
其中,Ar和Ar.sub.1各自独立地表示苯基或萘基或含氮、氧或硫杂环;Z表示化学键或含有至多5个碳原子的主链或总计至多7个碳原子的烷基链;X表示O或S;R和R.sub.1各自独立地表示氢、羟基、较低的烷氧基、较低的烷酰氧基、卤素、氰基、羧较低烷氧基、羧基较低烷基、芳氧基或苄氧基;R.sub.2、R.sub.3、R.sub.4和R.sub.5各自独立地表示氢、较低的烷基、较低的芳基烷基、较低的烯基、较低的炔基、芳基或羧较低烷基;其药学上可接受的盐具有药理活性,特别是作为脂氧合酶抑制剂具有抗炎和抗过敏性能。